Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B

Tze-Peng Lim, Winnie Lee, Thean-Yen Tan, Suranthran Sasikala, Jocelyn Teo, Li-Yang Hsu, Thuan-Tong Tan, Nur Syahidah, Andrea L Kwa, Tze-Peng Lim, Winnie Lee, Thean-Yen Tan, Suranthran Sasikala, Jocelyn Teo, Li-Yang Hsu, Thuan-Tong Tan, Nur Syahidah, Andrea L Kwa

Abstract

Objective: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objective of this study is to assess the in vitro activity of various antibiotics against local XDR-PA isolates.

Methods: PA isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs were determined according to CLSI guidelines. All XDR-PA isolates identified were genotyped using a PCR-based method. Time-kill studies (TKS) were performed with approximately 10(5) CFU/ml at baseline using clinically achievable unbound concentrations of amikacin (A), levofloxacin (L), meropenem (M), rifampicin (R) and PB alone and in combination. Bactericidal activity (primary endpoint) was defined as a ≥3 log(10) CFU/ml decrease in the colony count from the initial inoculum at 24 hours.

Results: 22 clinical XDR-PA isolates with PB MIC 2-16 µg/ml were collected. From clonal typing, 5 clonal groups were identified and nine isolates exhibited clonal diversity. In TKS, meropenem plus PB, amikacin plus meropenem, amikacin plus rifampicin, amikacin plus PB exhibited bactericidal activity in 8/22, 3/22, 1/22 and 6/22 isolates at 24 hours respectively. Against the remaining ten isolates where none of the dual-drug combination achieved bactericidal activity against, only the triple-antibiotic combinations of ARP and AMP achieved bactericidal activity against 7/10 and 6/10 isolates respectively.

Conclusion: Bactericidal activity with sustained killing effect of ≥99.9% is critical for eradicating XDR-PA infections, especially in immunocompromised hosts. These findings underscore the difficulty of developing combination therapeutic options against XDR-PA, demonstrating that at least 3 antibiotics are required in combination and that efficacy is strain dependant.

Conflict of interest statement

Competing Interests: T-YT and L-YH have received funding for research from, and have been an invited as speakers for Wyeth Pharmaceuticals and Pfizer. ALK, WL and T-PL have received funding for research from Janssen-Cilag, Pfizer.Inc & Merck Sharp & Dohme (I.A.) Corp. None of these companies provided any funding for this particular study. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Figure 1. Phylogenetic Tree Diagram showing clonal…
Figure 1. Phylogenetic Tree Diagram showing clonal groups.
A yellow oval shape denotes a clonal group after applying a similarity index of ≥90% to PCR typing results.

References

    1. Livermore DM. Introduction: the challenge of multiresistance. Int J Antimicrob Agents. 2007;29(Suppl 3):S1–7.
    1. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15:47–53.
    1. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis. 2005;18:306–313.
    1. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43(Suppl 2):S49–56.
    1. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582–610.
    1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2011
    1. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, et al. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010;54:1173–1178.
    1. Tan TY, Hsu LY, Koh TH, Ng LS, Tee NW, et al. Antibiotic resistance in gram-negative bacilli: a Singapore perspective. Ann Acad Med Singapore. 2008;37:819–825.
    1. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47:1298–1304.
    1. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36(Suppl 2):S50–54.
    1. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007;13:560–578.
    1. Clinical and Laboratory Standards Institute. Methods for Dilution: Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard- Eighth Edition., vol. 29. 2009. Clinical Laboratory Standards Institute,. Wayne, Pennsylvania, USA.
    1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial testing: Twenty-First Informational Supplement M100-S21. 2011. CLSI. Wayne, Pennsylvania, USA.
    1. Dawson SL, Fry JC, Dancer BN. A comparative evaluation of five typing techniques for determining the diversity of fluorescent pseudomonads. J Microbiol Methods. 2002;50:9–22.
    1. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, et al. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol. 2005;43:3129–3135.
    1. Ellington MJ, Kistler J, Livermore DM, Woodford N. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicrob Chemother. 2007;59:321–322.
    1. Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother. 1998;42:849–856.
    1. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337–1339.
    1. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51:3781–3788.
    1. Kwa AL, Lim TP, Low JG, Hou J, Kurup A, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008;60:163–167.
    1. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004;54:566–569.
    1. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003;47:2659–2662.
    1. Ostronoff M, Ostronoff F, Sucupira A, Souto Maior AP, Caniza M, et al. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis. 2006;10:339–340.
    1. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis. 2007;58:235–240.
    1. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30:315–319.
    1. Kwa AL, Tam VH, Falagas ME. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singapore. 2008;37:870–883.
    1. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811–821.
    1. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, et al. Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2005;49:4733–4738.
    1. Letendre ED, Mantha R, Turgeon PL. Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis. J Antimicrob Chemother. 1988;22:557–562.
    1. Danel F, Hall LM, Gur D, Livermore DM. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995;39:1881–1884.
    1. Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother. 2001;45:447–453.
    1. Koh TH, Wang GC, Sng LH. Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore. J Clin Microbiol. 2004;42:5378–5380.
    1. TT Tan TK, ML Ling, BH Tan. Molecular epidemiology and characterization of extensive drug-resistant Pseudomonas aeruginosa outbreak in a hematology unit. 2010. 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria.
    1. Kunin CM, Craig WA, Kornguth M, Monson R. Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci. 1973;226:214–224.
    1. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, et al. Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula. Antimicrob Agents Chemother. 2011;55:5134–5142.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren